Compare the Best Medical Writing Vendors

Who this guide is for

This guide is for clinical operations leads, regulatory affairs managers and biotech founders who need to outsource clinical and regulatory documents: a first protocol, an investigator brochure update, a clinical study report or the summaries that sit in a marketing application. It is also for teams deciding whether one partner can cover both regulatory and publication writing, or whether those should be bought separately.

If you are looking for the best medical writing vendors for clinical trials, treat the vendor cards above as a starting point, not a verdict. They show which medical writing vendors are listed and how each profile describes its focus; they cannot tell you whether a team has written your document type in your indication, or how it runs review cycles. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score. Use the criteria below to decide what to ask before you commit.

What a medical writing vendor does — and when you need one

A medical writing vendor turns trial design decisions, data and regulatory strategy into documents that ethics committees, regulators, investigators, journals and patients can rely on. The work splits into two disciplines. Regulatory writing covers the protocol and amendments, the investigator brochure, informed consent material, clinical study reports structured to ICH E3, and the clinical overview and summaries in Module 2 of the Common Technical Document. Publication writing covers manuscripts, congress abstracts and posters, and the publication plan behind them, governed by journal and Good Publication Practice expectations rather than regulators.

Writing vendors are distinct from biostatistics providers, who produce the tables, listings and figures a report interprets, and from regulatory consultancies, who own submission strategy and agency interaction. Many full-service CROs bundle writing with conduct; specialist writing houses sell it on its own.

Typical trigger points are a protocol needed faster than internal staff can deliver, a database lock that will produce a report on a fixed timeline, a dossier build, a new obligation to publish plain-language results, or a capacity gap after a writer leaves.

How to evaluate a medical writing vendor

Document-type experience, not just therapeutic labels

A writer who has drafted many manuscripts may never have assembled a clinical study report, and the reverse is equally common. Ask for redacted samples of the exact document type you are buying, written in the last few years, and for the named writer who produced each one. Therapeutic area matters, but document architecture matters more.

Command of the governing guidance

Probe how the team applies ICH E3 to report structure, what it expects of an investigator brochure under ICH E6(R3), how it handles the ICH M4E format for Module 2 summaries, and whether it is preparing for the ICH M11 harmonised protocol template. Writers who can explain where guidance is flexible, and why they made a choice, save review cycles later.

Plain-language and transparency writing

Under the EU Clinical Trials Regulation, Regulation (EU) No 536/2014, sponsors must post a lay summary of results in CTIS following the content set out in Annex V. Ask whether the vendor has written lay summaries for this purpose, how it tests readability with patient reviewers, and how it handles redaction and anonymisation of reports for public disclosure.

Quality control and review cycles

Ask for the written QC procedure: who checks numbers against source tables, whether data verification is a separate step from editorial review, and how comments from several reviewers are consolidated. Agree in advance how many review rounds the quote assumes and what happens when a sponsor reviewer misses a deadline.

Access to subject-matter experts

Strong writing depends on fast answers from statisticians, clinicians, pharmacovigilance and CMC specialists. Find out whether those experts sit inside the vendor or must be supplied by you, and who chairs the comment-resolution meeting.

Templates, tools and system compliance

Ask whether the vendor works in your templates or its own, how it manages styles and cross-references in long documents, and whether its document management system meets 21 CFR Part 11 expectations where electronic records and signatures are involved.

Continuity and team stability

Writing programmes span months or years. Ask who your lead writer is, how backup is arranged during absence, and how knowledge transfers if the writer moves on.

Medical writing vendors at a glance

The table below sets out the medical writing vendors tracked for this page side by side, so you can see at a glance how each profile describes its focus, footprint and study coverage before you open individual pages.

The fields come from each vendor's Clinical Vendor Compare profile. Read the table for what it is: most records here describe a stated specialism, such as publication planning, CMC writing or clinical study reports, rather than a full capability list. Only some profiles list study phases and trial scale, so a blank field means the record is silent, not that the vendor lacks the capability. Use each stated best fit to match vendors to the document you need, then confirm the rest in conversation.

Vendor profiles

Accel Research (Medical Writing)

Accel Research is listed as a medical writing vendor headquartered in the United States with a global footprint, covering Phase I to Phase IV studies of small and medium scale in oncology, CNS, infectious disease and cardiovascular medicine. Its stated best fit is documentation for US multi-site clinical trials. The strengths on its profile centre on a multi-therapeutic site network, clinical trial conduct and patient recruitment. Where to probe: because those strengths lean towards trial delivery, ask to meet the writers themselves and see samples of the specific documents you need.

Ashfield (Writing)

Ashfield's writing record lists it as a medical writing vendor with a global footprint and a generalist therapeutic remit. Its stated best fit is sponsors who want publication planning and writing, which points to publication work; confirm whether it also covers regulatory documents. The profile does not yet list study phases, trial scale or strengths. Where to probe: ask how publication planning links to your clinical study reports so that manuscripts and regulatory documents tell a consistent story, and how the team works within Good Publication Practice expectations.

CMC (Medical Writing)

This record describes a medical writing vendor with a global footprint and a generalist therapeutic remit, whose stated best fit is sponsors needing CMC regulatory writing. Chemistry, manufacturing and controls writing feeds the quality sections of a dossier, in Module 3 and its Module 2 quality summary, rather than the clinical documents. The profile does not yet list phases or trial scale. Where to probe: ask whether the team can also support clinical documents or will need to hand off to a clinical writing partner.

Mapi (Medical Writing)

Mapi's medical writing record lists a global footprint and a generalist therapeutic remit. Its stated best fit is sponsors wanting COA and PRO medical writing, meaning documentation for clinical outcome assessments and patient-reported outcome instruments. That work matters when an endpoint depends on a questionnaire whose development and validation must be explained to regulators. Where to probe: ask how outcome-measure documentation is integrated into the protocol, the statistical analysis narrative and the clinical study report, rather than delivered as a standalone dossier.

MedWrite (Medical Writing)

MedWrite is listed as a medical writing vendor headquartered in the United States with a global footprint, covering Phase I to Phase IV studies of small and medium scale across multiple therapeutic areas. Its stated best fit is sponsors wanting clinical study report writing. The strengths on its profile are regulatory medical writing, clinical study reports and investigator brochures, which point to regulatory work. Where to probe: ask how it aligns report structure with ICH E3 and how it runs data verification against source tables.

Niche (Medical Communications)

Niche's record lists it as a medical writing vendor with a global footprint and a generalist therapeutic remit. Its stated best fit is sponsors needing regulatory medical writing, which points to regulatory work, although the communications label in its name suggests confirming which side it covers. The profile does not yet list phases, trial scale or strengths. Where to probe: ask which regulatory document types it has delivered recently, and request redacted samples of the type you are buying.

PharmaWrite (Medical Writing)

PharmaWrite is listed as a medical writing vendor with a global footprint and a generalist therapeutic remit. Its stated best fit is sponsors wanting dedicated clinical medical writing. The profile does not yet list phases, trial scale or strengths, so confirm which clinical document types the team covers before shortlisting. Where to probe: ask whether dedicated means named writers assigned to your programme for its duration, and how backup cover is arranged.

Watermeadow (Medical Writing)

Watermeadow's record lists a medical writing vendor with a global footprint and a generalist therapeutic remit. Its stated best fit is European clinical trial medical writing, which makes it relevant to sponsors running studies under the EU Clinical Trials Regulation. The profile does not yet list phases, trial scale or strengths. Where to probe: ask about its experience with CTIS submissions, lay summaries prepared under Annex V, and documents for UK studies reviewed by the MHRA.

Engagement and pricing models

Medical writing is usually bought in one of three ways. Per-document or unit-based quotes price each deliverable, such as a protocol or a report, and suit sponsors with occasional, well-defined needs. FSP or FTE-based models embed one or more writers in your team for a period, giving continuity across a programme. Full-service bundles fold writing into a wider CRO contract alongside monitoring, data management and biostatistics.

The main cost drivers are document length and complexity, the volume of data to interpret, the number of review rounds assumed, the seniority of the writer and reviewer, turnaround pressure, and extras such as QC data verification, publishing, redaction or translation of lay summaries. Unit pricing is predictable but can penalise scope creep through change orders; FSP gives flexibility but needs internal management. Whichever model you choose, write the review-round assumption and change-order triggers into the contract.

Questions to put in your RFP

• Which of our documents have you written recently, and can you share redacted samples of each type?
• Who is the named lead writer, and who provides senior review?
• How do you apply ICH E3 to clinical study reports, including the use of the ICH E3 questions and answers?
• How many review rounds does your quote assume, and how are extra rounds charged?
• Describe your QC process: who verifies text against source tables, and is that independent of the author?
• Which subject-matter experts can you provide in-house, and which will you need from us?
• Have you written lay summaries under Regulation (EU) No 536/2014, and how do you test them with patients?
• Can you prepare Module 2 clinical summaries to the ICH M4E structure, and work with our publishing vendor?
• What document management system do you use, and does it support 21 CFR Part 11 controls?
• Will you work in our templates and style guide, or do you require your own?
• How do you handle anonymisation and redaction for public disclosure of reports?

Due-diligence red flags

• Samples that are all publications when you are buying regulatory documents, or the reverse.
• No named writer at proposal stage, or a senior name that disappears after signature.
• QC described only as proofreading, with no data verification against source outputs.
• Quotes that are silent on review rounds, leaving every extra cycle as a change order.
• Vague answers about ICH E3, Annex V lay summaries or Module 2 structure.
• Reliance on your team for every clinical or statistical question without saying so up front.
• No clear policy on confidentiality, data handling under GDPR, or use of AI drafting tools on your data.
• Reluctance to share a sample timeline showing draft, review and finalisation milestones.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter for medical writing to see every listed provider. Open profiles to check stated focus, then place two or three side by side on the compare page to separate regulatory specialists from publication-focused teams. When your scope is clear, use the sponsor RFP tool to brief vendors on the documents, timelines and review assumptions you need. If your search began with "medical writing CRO UK", filter the directory by geography and test each vendor's knowledge of MHRA and HRA expectations directly. If you have worked with any of these vendors, please write a review: published reviews are what give the next buyer an evidence base.